BioXcel Therapeutics (BTAI) Projected to Post Earnings on Monday

BioXcel Therapeutics (NASDAQ:BTAI) is expected to release its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect BioXcel Therapeutics to post earnings of ($0.5325) per share and revenue of $0.3870 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

BioXcel Therapeutics (NASDAQ:BTAI) last posted its earnings results on Friday, March 27th. The company reported ($0.58) EPS for the quarter, hitting the consensus estimate of ($0.58). On average, analysts expect BioXcel Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

BioXcel Therapeutics Stock Up 4.4%

NASDAQ BTAI traded up $0.05 on Monday, hitting $1.25. The stock had a trading volume of 215,832 shares, compared to its average volume of 1,293,926. BioXcel Therapeutics has a one year low of $1.01 and a one year high of $8.08. The stock has a market cap of $33.93 million, a price-to-earnings ratio of -0.19 and a beta of 0.31. The company’s 50-day moving average is $1.36 and its two-hundred day moving average is $1.69.

Analyst Upgrades and Downgrades

Several research firms have commented on BTAI. HC Wainwright decreased their target price on shares of BioXcel Therapeutics from $6.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, April 2nd. Zacks Research upgraded shares of BioXcel Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Monday, March 9th. Weiss Ratings restated a “sell (e+)” rating on shares of BioXcel Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded shares of BioXcel Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, April 25th. Finally, Rodman & Renshaw started coverage on shares of BioXcel Therapeutics in a research report on Tuesday, March 17th. They issued a “buy” rating and a $17.00 target price for the company. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, BioXcel Therapeutics currently has an average rating of “Hold” and a consensus target price of $11.00.

Institutional Trading of BioXcel Therapeutics

Institutional investors have recently made changes to their positions in the stock. Diversify Wealth Management LLC acquired a new stake in shares of BioXcel Therapeutics in the 2nd quarter worth approximately $27,000. HRT Financial LP acquired a new stake in shares of BioXcel Therapeutics in the 4th quarter worth approximately $28,000. XTX Topco Ltd acquired a new stake in shares of BioXcel Therapeutics in the 2nd quarter worth approximately $42,000. Goldman Sachs Group Inc. acquired a new stake in shares of BioXcel Therapeutics in the 1st quarter worth approximately $50,000. Finally, Geode Capital Management LLC lifted its stake in shares of BioXcel Therapeutics by 27.7% in the 2nd quarter. Geode Capital Management LLC now owns 28,182 shares of the company’s stock worth $51,000 after acquiring an additional 6,120 shares during the period. 30.68% of the stock is owned by institutional investors and hedge funds.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc is a biopharmaceutical company leveraging an AI-driven drug development platform to identify and advance novel or repurposed therapies in neuroscience and immunology. The proprietary BioXcel AI engine analyzes preclinical and clinical data to reveal new therapeutic applications for existing small molecules and biologics, aiming to streamline development timelines and improve patient outcomes.

BioXcel’s commercial portfolio includes two FDA-approved therapies. IGALMI® (dexmedetomidine) is indicated for the acute treatment of agitation in schizophrenia or bipolar I disorder, offering a noninvasive, sublingual delivery option.